5 Micro-Cap Stocks To Buy According To Cathie Wood

3. Surface Oncology, Inc. (NASDAQ:SURF)

Percentage of ARK Investment Management’s 13F Portfolio: 0.06%

ARK Investment Management’s Stake Value: $15.7 million

Number of Hedge Fund Holders: 12

Market Capitalization: $96.11 million

Surface Oncology, Inc. (NASDAQ:SURF) is a clinical-stage immuno-oncology company focused on developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. One of the top micro-cap stock in Cathie Wood’s 13F portfolio for the first  quarter of 2022, her hedge fund reported owning 5.34 million Surface Oncology, Inc. (NASDAQ:SURF) shares, worth $15.7 million

Earlier this April, Surface Oncology, Inc. (NASDAQ:SURF) announced the initiation of its two Phase 2 clinical studies evaluating SRF388, a potential first-in-class antibody against IL-27. The trials include a randomized Phase 2 clinical study evaluating SRF388 in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naive hepatocellular carcinoma, and a Phase 2 monotherapy study in patients with previously-treated non-small-cell lung cancer.

In Q1 2022, 12 hedge funds reported owning stakes in Surface Oncology, Inc. (NASDAQ:SURF), worth $46.4 million. This is compared to 13 funds holding stakes in the company valued at $42.39 million in the preceding quarter. Ken Griffin’s Citadel Investment Group is one of the biggest stakeholders in Surface Oncology, Inc. (NASDAQ:SURF), with 1.4 million shares worth more than $4.13 million.